Lung Squamous Cell Carcinoma (LUSC)

Overview

Lung Squamous Cell Carcinoma is a Non-Small Cell Lung Cancer histology (parent NSCLC).

Cohorts in the corpus

  • nsclc_ctdx_msk_2022: LUSC was included alongside LUAD in the 1,127-patient advanced NSCLC ctDNA cohort profiled by Resolution Bioscience ctDx Lung at MSK and GenesisCare PMID:36357680.
  • bm_nsclc_mskcc_2023: 23/233 (10%) of the resected NSCLC brain metastasis cohort were LUSC PMID:37591896.
  • Bakr 2018 published the NSCLC-Radiogenomics Stanford cohort with 45/211 patients being LUSC; pre-treatment CT imaging paired with RNA-seq and somatic mutation data, providing an imaging-genomics resource for LUSC PMID:30325352.

Recurrent alterations

  • STK11 alterations differ in BM subtype: 22% in LUAD BM vs 0% in SCC BM (p=0.01) PMID:37591896.
  • Analyzed within the broader NSCLC ctDNA cohort where pathogenic TP53, EGFR, or KRAS alterations detected in ctDNA (vs tissue only) were associated with worse prognosis PMID:36357680.
  • In a 247-patient advanced NSCLC cohort (15% squamous/LUSC), multimodal DyAM model integrating CT radiomics, PD-L1 IHC, and genomics achieved AUC=0.80 for ICI response prediction; the model handles missing modalities and provides modality-specific risk scores enabling clinical interpretability PMID:36038778
  • TCGA WES of 178 lung squamous cell carcinomas defined the genomic landscape: near-universal CDKN2A loss, TP53 mutation, and frequent KEAP1/NFE2L2 alterations PMID:22960745
  • Pan-NSCLC WES of 660 LUAD and 484 LUSC tumour/normal pairs (nsclc_tcga_broad_2016); LUSC had median somatic mutation rate 9.7/Mb and 20 SMGs; novel LUSC driver RASA1; TP53, CDKN2A, and PIK3CA were significantly more frequently mutated in LUSC than LUAD (p<0.01); LUSC genetic landscape more closely resembled HNSC and BLCA than LUAD; 53% of LUSCs had ≥5 predicted neoepitopes PMID:27158780
  • LUSC had a 97% pre-operative ctDNA detection rate (30/31 cases) in the TRACERx cohort, compared with 19% for LUAD; non-adenocarcinoma histology, lymphovascular invasion, and high Ki67 were independent predictors of ctDNA detection on multivariable logistic regression. PMID:28445469
  • Squamous cell lung cancer comprised 14% (34/240) of the anti-PD-(L)1 NSCLC MSK-IMPACT cohort used to validate targeted NGS-based TMB as an immunotherapy biomarker; LUSC mutational signatures were used as a comparison reference in the vulvar SCC WES landscape study PMID:29337640
  • LUSC mutational signatures (TCGA) were used as a reference comparison cohort in the first whole-exome sequencing landscape of vulvar squamous cell carcinoma; signature profiles were compared across HPV(+) and HPV(-) etiologic subgroups PMID:29422544
  • MC3 pan-cancer mutation-calling project (10,510 TCGA pairs) included LUSC; LUSC and LUAD had the largest median SNVs per sample, consistent with tobacco-mutagen exposure PMID:29596782
  • Pan-cancer fusion study (9,624 TCGA samples) identified FGFR3–TACC3 in 1.2% of LUSC samples; FGFR3 is a druggable target across 15 cancer types PMID:29617662
  • Pan-cancer aneuploidy study placed LUSC in the squamous arm-level cluster (chr_3p loss + chr_3q gain); chr_3p was deleted in ~80% of LUSC tumors and chr_3q gained in >60%; co-occurrence was significantly above chance (chi-square p = 0.0386); the squamous signature was most prominent in LUSC PMID:29622463

Subtypes

  • Not further subdivided in this corpus.

Therapeutic landscape

  • ctDNA detection is an independent poor prognostic marker in advanced NSCLC (HR 2.05, P<0.001), with ctDNA-guided matching to targeted therapy conferring OS benefit (HR 0.63, P<0.001) PMID:36357680.
  • ATLAS RNA-expression classifier (trained on 8,249 samples including TCGA/CCLE) achieved 91.4% accuracy for cancer site classification; LUSC distinguished within the 22-class site classifier with lineage de-differentiation score prognostic for survival (HR 0.24, P=0.001) PMID:27634761.

Sources

This page was processed by crosslinker on 2026-05-06. - PMID:22960745

This page was processed by wiki-cli on 2026-05-06. - PMID:27158780

This page was processed by entity-page-writer on 2026-05-15. - PMID:29337640 - PMID:29422544

This page was processed by entity-page-writer on 2026-05-15. - PMID:29596782

This page was processed by wiki-cli on 2026-05-15. - PMID:29617662

This page was processed by wiki-cli on 2026-05-15. - PMID:29622463

This page was processed by wiki-cli on 2026-05-15.